Search

Your search keyword '"Labbe, Kristen"' showing total 31 results
Start Over Author "Labbe, Kristen"
31 results on '"Labbe, Kristen"'

1. Investigation of a Mobile Health Texting Tool for Embedding Patient-Reported Data Into Diabetes Management (i-Matter): Development and Usability Study

Author

Schoenthaler, Antoinette, Cruz, Jocelyn, Payano, Leydi, Rosado, Marina, Labbe, Kristen, Johnson, Chrystal, Gonzalez, Javier, Patxot, Melissa, Patel, Smit, Leven, Eric, and Mann, Devin

Subjects
Medicine
Abstract

BackgroundPatient-reported outcomes (PROs) are increasingly being used in the management of type 2 diabetes (T2D) to integrate data from patients’ perspective into clinical care. To date, the majority of PRO tools have lacked patient and provider involvement in their development, thus failing to meet the unique needs of end users, and lack the technical infrastructure to be integrated into the clinic workflow. ObjectiveThis study aims to apply a systematic, user-centered design approach to develop i-Matter (investigating a mobile health [mHealth] texting tool for embedding patient-reported data into diabetes management), a theory-driven, mobile PRO system for patients with T2D and their primary care providers. Methodsi-Matter combines text messaging with dynamic data visualizations that can be integrated into electronic health records (EHRs) and personalized patient reports. To build i-Matter, we conducted semistructured group and individual interviews with patients with T2D and providers, a design thinking workshop to refine initial ideas and design the prototype, and user testing sessions of prototypes using a rapid-cycle design (ie, design-test-modify-retest). ResultsUsing an iterative user-centered process resulted in the identification of 6 PRO messages that were relevant to patients and providers: medication adherence, dietary behaviors, physical activity, sleep quality, quality of life, and healthy living goals. In user testing, patients recommended improvements to the wording and timing of the PRO text messages to increase clarity and response rates. Patients also recommended including motivational text messages to help sustain engagement with the program. The personalized report was regarded as a key tool for diabetes self-management by patients and providers because it aided in the identification of longitudinal patterns in the PRO data, which increased patient awareness of their need to adopt healthier behaviors. Patients recommended adding individualized tips to the journal on how they can improve their behaviors. Providers preferred having a separate tab built into the EHR that included the personalized report and highlighted key trends in patients’ PRO data over the past 3 months. ConclusionsPRO tools that capture patients’ well-being and the behavioral aspects of T2D management are important to patients and providers. A clinical trial will test the efficacy of i-Matter in 282 patients with uncontrolled T2D. Trial RegistrationClinicalTrials.gov NCT03652389; https://clinicaltrials.gov/ct2/show/NCT03652389

Published
2020
Full Text
View/download PDF

4. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Author

Miller, Timothy M, Cudkowicz, Merit E, Andrews, Jinsy A, Hesters, Adele, Kermorvant, Hugo, Lacomblez, Lucette, Forestier, Nadine Le, Lenglet, Thimotée, Retail, Maryvonne, Ruiz Del Mar Amador, Maria, Salachas, François, Shotar, Eimad, Sourour, Nader, Babu, Suma, Dorst, Johannes, Froehlich, Elke, Fromm, Andrea, Kandler, Katharina, Langer, Eva, Leichtle, Sarah, Ludolph, Albert, Mayer, Kristina, Michels, Sebastian, Raubold, Sabine, Benatar, Michael, Schuster, Joachim, Weiland, Ulrike, Wiesenfarth, Maximilian, Witzel, Simon, Calvo, Andrea, Canosa, Antonio, Casale, Federico, Chiò, Adriano, Fuda, Giuseppe, Grassano, Maurizio, McDermott, Christopher J, Marchese, Giulia, Moglia, Cristina, Palumbo, Francesca, Salamone, Paolina, Ajiki, Takahiro, Akasaka, Aya, Ando, Masahiro, Arata, Hitoshi, Asuka, Kitamura, Baba, Kosuke, Cochrane, Thos, Bekku, Goichi, Chiba, Tomoya, Date, Yugaku, Eriko, Takeuchi, Hashiguchi, Akihiro, Hatatori, Ritsuko, Hayano, Eri, Hayashi, Yuto, Higashi, Keiko, Higuchi, Eriko, Chary, Sowmya, Hiramatsu, Yu, Horikawa, Rui, Ikenaka, Kensuke, Ishiura, Hiroyuki, Ito, Daisuke, Kawai, Sachiko, Kikuchi, Junko, Kuzuyama, Haruko, Li, Xuehong, Matsumoto, Chika, Chew, Sheena, Matsuura, Eiji, Michizono, Kumiko, Mitsui, Jun, Mitsutake, Akihiko, Mochizuki, Hideki, Nagamatsu, Akemi, Nagano, Seiichi, Nakamura, Tomonori, Naruse, Hiroya, Ogasawara, Asuka, Zhu, Han, Okada, Kensuke, Okamoto, Yuji, Okuno, Tatsusada, Oyama, Satoshi, Ozono, Tatsuhiko, Sakiyama, Yusuke, Sakuishi, Kaori, Seki, Morinobu, Shibata, Shota, Shimizu, Mikito, Wu, Fan, Takahata, Katsunori, Takahito, Yoshizaki, Takashima, Hiroshi, Takeichi, Hiroko, Tashiro, Yuichi, Toda, Tatsushi, Tomizu, Yuki, Tomoya, Wadayama, Ujiakira, Nishiike, Yashita, Daiki, Nestorov, Ivan, Al-Chalabi, Ammar, Alix, James, Bangalore, Priyadarshini, Blackburn, Daniel, Chiwera, Theresa, Clegg, Rosie, Collins, Alexis, Cooper-Knock, Jonathan, Emery, Anna, Franklin, John, Genge, Angela, Graham, Danielle, Green, Louisa, Harvey, Callum, Hobson, Esther, Islam, Mahjabim, Jenkins, Thomas Michael, Kazoka, Mbombe, Kelly, Gillian, Korley, Mercy, Madarshahaian, Daniel, Mayl, Keith, Sun, Peng, McDermott, Christopher John, Radford, Alex, Shaw, Christopher, Shaw, Pamela J, Sidebottom, Joe, Smart, Lynne, Sreedharan, Jemeen, Stone, Ben, Tsironis, Theocharis, Tuddenham, Lee, McNeill, Manjit, Verber, Nick, Wollff, Helen, Young, Stacy, Zis, Panagiotis, Adamo, Ashley, Ahmed, Arubah, Ajroud-Driss, Senda, Alameda, Gustave, Arcila-Londono, Ximena, Fanning, Laura, Baird, Candy, Bazan, Tracy, Berry, James, Bordeau, Jane, Bradford, Wendy, Brook, Nyda, Brown, Lauren, Bucelli, Robert C, Ferguson, Toby A, Buckner, Katherine, Budler, Michael W, Burba, Lindita, Burke, Katherine, Calhoun, Ashley D, Campbell, Sarah, Carey, Judith, Caristo, Irys B, Carty, Simon, Chan, Emmanuel, Fradette, Stephanie, Chaudhry, Vinay, Chen, Ricky, Chow, Saephanh, Clawson, Lora L, Clemens, Mitchell, Cloninger, Suzann E, Coleman-Wood, Krista, Cooper, Thomas N, Cummings, Arlena, Daniels, Jacquelyn, VALOR, DeSaro, Pamela, DeWitt, Michelle, Dedi, Brixhilda, Dempsey, Debbie, Denny, Carol, Doherty, Jenna, Doherty, Leana, Donahue, Megan, Doyle, Michael, Duncan, Jessie, Group, OLE Working, Elman, Lauren, Eloge, Christine M, Echiti, Desirae R, Ferrey, Dominic, Fournier, Christina, Fukumura, Yuriko, Gallagher, Katherine, Garaycoa, Jessica, Garrett, Mark, Gibson, Richard L, Beullens, Lien, Gifford, Ryan, Glass, Jonathan D, Gogol, Danuta, Golden, Shea, Gonzalez, Alexa, Goodman, Ira, Goolsby, Christopher, Goslin, Kimberly, Goulbourne, Michael, Granit, Volkan, Claeys, Kristl, Grignon, Anne-Laure, GuhaRay, Adreeja, Guide, Debra, Gundogdu, Melek Betul, Gutierrez, Gil, Hastings, Debbie, Hayzen, Colleen, Herzog, Hilary, Holloway, Raegan, Jacobs, Gabriel, Claeys, Thomas, Jacobsen, Bill, James, Virginia, Jenkins, Liberty, Jockel-Balsarotti, Jennifer, Johnson, Linda Carol, Jose, Sunil, Joslin, Benjamin, Karanja, Elizabeth, Katz, Jonathan, Keener, Anthony, Couwelier, Goedele, Kittle, Gale, Klein, Sara, Kreple, Collin, Rebecca, Rebecca, Kuenzler, Kuenzler, Kusnir, Jorge, Labbe, Kristen, Lachica-Encinas, Nicolet, Ladha, Shafeeq, Leimer, Lesli, D'Hondt, Ann, Levy, Michael, Levy, Wendy, Li, Yingji, Likanje, Marie-France, Livigni, Rebecca, Locatelli, Eduardo, Luppino, Sarah, Malcolm, Amber, Maragakis, Nicholas, Marin, Horia, Debien, Elisa, Markowitz, Clyde, Markway, Jesse, McCaffrey, Alexandra, McCoy, Arita, McCoy Gross, Kelly, Mehta, Kush, Meyer, Robert, Milan, Jennifer, Miller, Timothy, Miller, Robert G, de Keersmaecker, Sebastiaan, Morales, Francisco, Mosmiller, Elizabeth, Mott, Donovan, Moulton, Kelsey, Murphy, Christine A, Negron, Tirso, Nelson, Cassandra, Newman, Daniel S, Nissinen, Janne Kristoffer, Norman, Andrew, Della Faille, Laetitia, Ohkubo, Takuya, Olney, Nicholas, Ortiz, Natasha, Oskarsson, Bjorn, Pace, Mitchell, Packard, Kathleen, Padgett, Denny, Paganoni, Sabrina, Paredes, Maria E, Parker, Elizabeth, Delmotte, Koen, Partlow, Ann, Pattee, Gary L, Paulett, Jany, Pelot, Antoinette, Pfeifer, Kyle M, Pijanowski, Olivia, Pioro, Erik, Polak, Meraida, Prakash, Ahalya, Previte, Rosemarie, Depoortere, Sofie, Pukenas, Bryan, Quinn, Colin, Ravits, John, Razavi, Ryan, Regan, Tyler, Riley, Kristen M, Roth, Heather, Sanders, Danica, Scalia, Jennifer, Schmidt, Emma, de Velder, Laura, Schwen, Edward, Shah, Jaimin, Shah, Stuti, Shefner, Jeremy, Sheldon, Danielle, Simmons, Karon, Singh, Navneet K, Singleton, Jessica, Smiley, Richard, Smith, William B, Dobbels, Laurens, Smith, Sean, Sotirchos, Elias, Sorenson, Eric, Staff, Nathan, Steele, Julie, Steijlen, Kara, Stirrat, Taylor, Stoica, George S, Strong, Stephanie, Sufit, Robert, Sobue, Gen, Gijs, Jeroen, Sultze, Jane, Swartz, Amy, Szymanski, April, Tay, Anna, Thakore, Nimish, Thiessen, Diana, Thotala, Sukrutha, Trudell, Randall G, Turcotte, Nicole, Turner, Michelle, Horckmans, Simon, Uchil, Alpa, Upadhyay, Vihar, Usman, Uzma, Vallis, Anne, Vaporean-Bussey, Danielle, Vladimirova, Valentine, Weber, Harli, Winbigler, Jennifer, Wojanowski, Heather, Wulf, Charlie, Lamaire, Nikita, Yasek, Julia, Yoo, Stephanie, Zivalic, Hannah, Cole, Alexandra, File, Greta, Foate, Jeremy, Mason, Deborah, Newton, Susan, Roberts, Stephen, Sellwood, Cory Dean, Liessens, Hannelore, Swan, James, Werno, Anja, Zhong, Cathy, Masrori, Pegah, Nysten, Celine, Schotte, Caroline, Serrien, Anouk, Swinnen, Bart, Tilkin, Petra, van Daele, Sien, Van Damme, Philip, Vynckier, Jan, Wouters, Anke, Abrahao, Agessandro, Angle, Mark, Badawy, Mohamed, Berube, Maxime, Bertone, Vanessa, Cooper, Sarah Marie, Dobrowolski, Peter, Fong, Helen, Hannouche, Matthew, Hartley, Denise, Hogan, Michael, Johnston, Wendy, Khalfallah, Yousra, Korngut, Lawrence, Kroetsch, Gina, Letourneau, Justin, Magnussen, Claire, Martinez, Jose, Massie, Rami, Mobach, Theodore, Mookshah, Jahan, Ozelsel, Timur, Parks, Andrea, Petrillo, Janet, Pfeffer, Gerald, Ludolph, Albert C, Pham, Shirley, Phung, Liane, Shiungsun, Rodney, Pi-Shan, Li, Santos, Denizart, Salmon, Kristiana, Saunders, Natalie, Sembinelli, Dylan, Tymkow, Kelsey, Wong, Berchman, Zinman, Lorne, Karlsborg, Merete, Pedersen Lomholt, Therese, Nilsson, Sigrid, Salvesen, Lisette, Skov, Pernille, Svenstrup, Kristen, Bruneteau, Gaelle, Calerencon, Frederic, and Guimaraes Costa, Raquel

Subjects
Adult, drug effects [Recovery of Function], Spinal, Oligonucleotides, blood [Neurofilament Proteins], administration & dosage [Oligonucleotides, Antisense], tofersen, Injections, blood [Amyotrophic Lateral Sclerosis], pharmacology [Oligonucleotides, Antisense], Superoxide Dismutase-1, Double-Blind Method, Neurofilament Proteins, Humans, ddc:610, Antisense, Injections, Spinal, Biomarkers, Recovery of Function, Amyotrophic Lateral Sclerosis, Oligonucleotides, Antisense, blood [Biomarkers], drug therapy [Amyotrophic Lateral Sclerosis], therapeutic use [Oligonucleotides, Antisense], SOD1 protein, human, General Medicine, genetics [Superoxide Dismutase-1], genetics [Amyotrophic Lateral Sclerosis], cerebrospinal fluid [Biomarkers], cerebrospinal fluid [Superoxide Dismutase-1], cerebrospinal fluid [Amyotrophic Lateral Sclerosis]
Abstract

The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with mutations in SOD1 (SOD1 ALS).In this phase 3 trial, we randomly assigned adults with SOD1 ALS in a 2:1 ratio to receive eight doses of tofersen (100 mg) or placebo over a period of 24 weeks. The primary end point was the change from baseline to week 28 in the total score on the ALS Functional Rating Scale-Revised (ALSFRS-R; range, 0 to 48, with higher scores indicating better function) among participants predicted to have faster-progressing disease. Secondary end points included changes in the total concentration of SOD1 protein in cerebrospinal fluid (CSF), in the concentration of neurofilament light chains in plasma, in slow vital capacity, and in handheld dynamometry in 16 muscles. A combined analysis of the randomized component of the trial and its open-label extension at 52 weeks compared the results in participants who started tofersen at trial entry (early-start cohort) with those in participants who switched from placebo to the drug at week 28 (delayed-start cohort).A total of 72 participants received tofersen (39 predicted to have faster progression), and 36 received placebo (21 predicted to have faster progression). Tofersen led to greater reductions in concentrations of SOD1 in CSF and of neurofilament light chains in plasma than placebo. In the faster-progression subgroup (primary analysis), the change to week 28 in the ALSFRS-R score was -6.98 with tofersen and -8.14 with placebo (difference, 1.2 points; 95% confidence interval [CI], -3.2 to 5.5; P = 0.97). Results for secondary clinical end points did not differ significantly between the two groups. A total of 95 participants (88%) entered the open-label extension. At 52 weeks, the change in the ALSFRS-R score was -6.0 in the early-start cohort and -9.5 in the delayed-start cohort (difference, 3.5 points; 95% CI, 0.4 to 6.7); non-multiplicity-adjusted differences favoring early-start tofersen were seen for other end points. Lumbar puncture-related adverse events were common. Neurologic serious adverse events occurred in 7% of tofersen recipients.In persons with SOD1 ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events. The potential effects of earlier as compared with delayed initiation of tofersen are being further evaluated in the extension phase. (Funded by Biogen; VALOR and OLE ClinicalTrials.gov numbers, NCT02623699 and NCT03070119; EudraCT numbers, 2015-004098-33 and 2016-003225-41.).

Published
2022

5. Figure S2 from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Author

Li, Fei, primary, Huang, Qingyuan, primary, Luster, Troy A., primary, Hu, Hai, primary, Zhang, Hua, primary, Ng, Wai-Lung, primary, Khodadadi-Jamayran, Alireza, primary, Wang, Wei, primary, Chen, Ting, primary, Deng, Jiehui, primary, Ranieri, Michela, primary, Fang, Zhaoyuan, primary, Pyon, Val, primary, Dowling, Catríona M., primary, Bagdatlioglu, Ece, primary, Almonte, Christina, primary, Labbe, Kristen, primary, Silver, Heather, primary, Rabin, Alexandra R., primary, Jani, Kandarp, primary, Tsirigos, Aristotelis, primary, Papagiannakopoulos, Thales, primary, Hammerman, Peter S., primary, Velcheti, Vamsidhar, primary, Freeman, Gordon J., primary, Qi, Jun, primary, Miller, George, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

6. Data from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Author

Li, Fei, primary, Huang, Qingyuan, primary, Luster, Troy A., primary, Hu, Hai, primary, Zhang, Hua, primary, Ng, Wai-Lung, primary, Khodadadi-Jamayran, Alireza, primary, Wang, Wei, primary, Chen, Ting, primary, Deng, Jiehui, primary, Ranieri, Michela, primary, Fang, Zhaoyuan, primary, Pyon, Val, primary, Dowling, Catríona M., primary, Bagdatlioglu, Ece, primary, Almonte, Christina, primary, Labbe, Kristen, primary, Silver, Heather, primary, Rabin, Alexandra R., primary, Jani, Kandarp, primary, Tsirigos, Aristotelis, primary, Papagiannakopoulos, Thales, primary, Hammerman, Peter S., primary, Velcheti, Vamsidhar, primary, Freeman, Gordon J., primary, Qi, Jun, primary, Miller, George, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

7. Table S1 from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Author

Li, Fei, primary, Huang, Qingyuan, primary, Luster, Troy A., primary, Hu, Hai, primary, Zhang, Hua, primary, Ng, Wai-Lung, primary, Khodadadi-Jamayran, Alireza, primary, Wang, Wei, primary, Chen, Ting, primary, Deng, Jiehui, primary, Ranieri, Michela, primary, Fang, Zhaoyuan, primary, Pyon, Val, primary, Dowling, Catríona M., primary, Bagdatlioglu, Ece, primary, Almonte, Christina, primary, Labbe, Kristen, primary, Silver, Heather, primary, Rabin, Alexandra R., primary, Jani, Kandarp, primary, Tsirigos, Aristotelis, primary, Papagiannakopoulos, Thales, primary, Hammerman, Peter S., primary, Velcheti, Vamsidhar, primary, Freeman, Gordon J., primary, Qi, Jun, primary, Miller, George, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

8. Table S1 from Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Author

Li, Fei, primary, Ng, Wai-Lung, primary, Luster, Troy A., primary, Hu, Hai, primary, Sviderskiy, Vladislav O., primary, Dowling, Catríona M., primary, Hollinshead, Kate E.R., primary, Zouitine, Paula, primary, Zhang, Hua, primary, Huang, Qingyuan, primary, Ranieri, Michela, primary, Wang, Wei, primary, Fang, Zhaoyuan, primary, Chen, Ting, primary, Deng, Jiehui, primary, Zhao, Kai, primary, So, Hon-Cheong, primary, Khodadadi-Jamayran, Alireza, primary, Xu, Mousheng, primary, Karatza, Angeliki, primary, Pyon, Val, primary, Li, Shuai, primary, Pan, Yuanwang, primary, Labbe, Kristen, primary, Almonte, Christina, primary, Poirier, John T., primary, Miller, George, primary, Possemato, Richard, primary, Qi, Jun, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure from DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome

Author

Guidry, Kayla, primary, Vasudevaraja, Varshini, primary, Labbe, Kristen, primary, Mohamed, Hussein, primary, Serrano, Jonathan, primary, Guidry, Brett W., primary, DeLorenzo, Michael, primary, Zhang, Hua, primary, Deng, Jiehui, primary, Sahu, Soumyadip, primary, Almonte, Christina, primary, Moreira, Andre L., primary, Tsirigos, Aristotelis, primary, Papagiannakopoulos, Thales, primary, Pass, Harvey, primary, Snuderl, Matija, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data from DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome

Author

Guidry, Kayla, primary, Vasudevaraja, Varshini, primary, Labbe, Kristen, primary, Mohamed, Hussein, primary, Serrano, Jonathan, primary, Guidry, Brett W., primary, DeLorenzo, Michael, primary, Zhang, Hua, primary, Deng, Jiehui, primary, Sahu, Soumyadip, primary, Almonte, Christina, primary, Moreira, Andre L., primary, Tsirigos, Aristotelis, primary, Papagiannakopoulos, Thales, primary, Pass, Harvey, primary, Snuderl, Matija, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

11. Data from Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Author

Li, Fei, primary, Ng, Wai-Lung, primary, Luster, Troy A., primary, Hu, Hai, primary, Sviderskiy, Vladislav O., primary, Dowling, Catríona M., primary, Hollinshead, Kate E.R., primary, Zouitine, Paula, primary, Zhang, Hua, primary, Huang, Qingyuan, primary, Ranieri, Michela, primary, Wang, Wei, primary, Fang, Zhaoyuan, primary, Chen, Ting, primary, Deng, Jiehui, primary, Zhao, Kai, primary, So, Hon-Cheong, primary, Khodadadi-Jamayran, Alireza, primary, Xu, Mousheng, primary, Karatza, Angeliki, primary, Pyon, Val, primary, Li, Shuai, primary, Pan, Yuanwang, primary, Labbe, Kristen, primary, Almonte, Christina, primary, Poirier, John T., primary, Miller, George, primary, Possemato, Richard, primary, Qi, Jun, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Author

Li, Fei, primary, Ng, Wai-Lung, primary, Luster, Troy A., primary, Hu, Hai, primary, Sviderskiy, Vladislav O., primary, Dowling, Catríona M., primary, Hollinshead, Kate E.R., primary, Zouitine, Paula, primary, Zhang, Hua, primary, Huang, Qingyuan, primary, Ranieri, Michela, primary, Wang, Wei, primary, Fang, Zhaoyuan, primary, Chen, Ting, primary, Deng, Jiehui, primary, Zhao, Kai, primary, So, Hon-Cheong, primary, Khodadadi-Jamayran, Alireza, primary, Xu, Mousheng, primary, Karatza, Angeliki, primary, Pyon, Val, primary, Li, Shuai, primary, Pan, Yuanwang, primary, Labbe, Kristen, primary, Almonte, Christina, primary, Poirier, John T., primary, Miller, George, primary, Possemato, Richard, primary, Qi, Jun, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

13. KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition

Author

Pan, Yuanwang, primary, Han, Han, additional, Hu, Hai, additional, Wang, Hua, additional, Song, Yueqiang, additional, Hao, Yuan, additional, Tong, Xinyuan, additional, Patel, Ayushi S., additional, Misirlioglu, Selim, additional, Tang, Sittinon, additional, Huang, Hsin-Yi, additional, Geng, Ke, additional, Chen, Ting, additional, Karatza, Angeliki, additional, Sherman, Fiona, additional, Labbe, Kristen E., additional, Yang, Fan, additional, Chafitz, Alison, additional, Peng, Chengwei, additional, Guo, Chenchen, additional, Moreira, Andre L., additional, Velcheti, Vamsidhar, additional, Lau, Sally C.M., additional, Sui, Pengfei, additional, Chen, Haiquan, additional, Diehl, J. Alan, additional, Rustgi, Anil K., additional, Bass, Adam J., additional, Poirier, John T., additional, Zhang, Xiaoyang, additional, Ji, Hongbin, additional, Zhang, Hua, additional, and Wong, Kwok-Kin, additional

Published
2023
Full Text
View/download PDF

14. Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Author

Pan, Yuanwang, primary, Hao, Yuan, additional, Han, Han, additional, Chen, Ting, additional, Ding, Hailin, additional, Labbe, Kristen E, additional, Shum, Elaine, additional, Guidry, Kayla, additional, Hu, Hai, additional, Sherman, Fiona, additional, Geng, Ke, additional, Stephens, Janaye, additional, Chafitz, Alison, additional, Tang, Sittinon, additional, Huang, Hsin-Yi, additional, Peng, Chengwei, additional, Almonte, Christina, additional, Lopes, Jared E, additional, Losey, Heather C, additional, Winquist, Raymond J, additional, Velcheti, Vamsidhar, additional, Zhang, Hua, additional, and Wong, Kwok-Kin, additional

Published
2022
Full Text
View/download PDF

15. DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome

Author

Guidry, Kayla, primary, Vasudevaraja, Varshini, additional, Labbe, Kristen, additional, Mohamed, Hussein, additional, Serrano, Jonathan, additional, Guidry, Brett W., additional, DeLorenzo, Michael, additional, Zhang, Hua, additional, Deng, Jiehui, additional, Sahu, Soumyadip, additional, Almonte, Christina, additional, Moreira, Andre L., additional, Tsirigos, Aristotelis, additional, Papagiannakopoulos, Thales, additional, Pass, Harvey, additional, Snuderl, Matija, additional, and Wong, Kwok-Kin, additional

Published
2022
Full Text
View/download PDF

16. Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer

Author

Huang, Qingyuan, primary, Li, Fei, additional, Hu, Hai, additional, Fang, Zhaoyuan, additional, Gao, Zhendong, additional, Xia, Guozhan, additional, Ng, Wai-Lung, additional, Khodadadi-Jamayran, Alireza, additional, Chen, Ting, additional, Deng, Jiehui, additional, Zhang, Hua, additional, Almonte, Christina, additional, Labbe, Kristen, additional, Han, Han, additional, Geng, Ke, additional, Tang, Sittinon, additional, Freeman, Gordon J., additional, Li, Yuan, additional, Chen, Haiquan, additional, and Wong, Kwok-Kin, additional

Published
2022
Full Text
View/download PDF

17. Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity

Author

Hu, Hai, primary, Khodadadi-Jamayran, Alireza, additional, Dolgalev, Igor, additional, Cho, Hyunwoo, additional, Badri, Sana, additional, Chiriboga, Luis A., additional, Zeck, Briana, additional, Lopez De Rodas Gregorio, Miguel, additional, Dowling, Catríona M., additional, Labbe, Kristen, additional, Deng, Jiehui, additional, Chen, Ting, additional, Zhang, Hua, additional, Zappile, Paul, additional, Chen, Ze, additional, Ueberheide, Beatrix, additional, Karatza, Angeliki, additional, Han, Han, additional, Ranieri, Michela, additional, Tang, Sittinon, additional, Jour, George, additional, Osman, Iman, additional, Sucker, Antje, additional, Schadendorf, Dirk, additional, Tsirigos, Aristotelis, additional, Schalper, Kurt A., additional, Velcheti, Vamsidhar, additional, Huang, Hsin-yi, additional, Jin, Yujuan, additional, Ji, Hongbin, additional, Poirier, John T., additional, Li, Fei, additional, and Wong, Kwok-Kin, additional

Published
2021
Full Text
View/download PDF

20. Response to Cottu, Bozec, Basse, and Paoletti

Author

Zhang, Hua, primary, Han, Han, additional, He, Tianhui, additional, Labbe, Kristen E, additional, Hernandez, Adrian V, additional, Chen, Haiquan, additional, Velcheti, Vamsidhar, additional, Stebbing, Justin, additional, and Wong, Kwok-Kin, additional

Published
2021
Full Text
View/download PDF

22. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment

Author

Deng, Jiehui, primary, Thennavan, Aatish, additional, Shah, Suhagi, additional, Bagdatlioglu, Ece, additional, Klar, Natalie, additional, Heguy, Adriana, additional, Marier, Christian, additional, Meyn, Peter, additional, Zhang, Yutong, additional, Labbe, Kristen, additional, Almonte, Christina, additional, Krogsgaard, Michelle, additional, Perou, Charles M., additional, Wong, Kwok-Kin, additional, and Adams, Sylvia, additional

Published
2020
Full Text
View/download PDF

23. Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Author

Li, Fei, primary, Ng, Wai-Lung, additional, Luster, Troy A., additional, Hu, Hai, additional, Sviderskiy, Vladislav O., additional, Dowling, Catríona M., additional, Hollinshead, Kate E.R., additional, Zouitine, Paula, additional, Zhang, Hua, additional, Huang, Qingyuan, additional, Ranieri, Michela, additional, Wang, Wei, additional, Fang, Zhaoyuan, additional, Chen, Ting, additional, Deng, Jiehui, additional, Zhao, Kai, additional, So, Hon-Cheong, additional, Khodadadi-Jamayran, Alireza, additional, Xu, Mousheng, additional, Karatza, Angeliki, additional, Pyon, Val, additional, Li, Shuai, additional, Pan, Yuanwang, additional, Labbe, Kristen, additional, Almonte, Christina, additional, Poirier, John T., additional, Miller, George, additional, Possemato, Richard, additional, Qi, Jun, additional, and Wong, Kwok-Kin, additional

Published
2020
Full Text
View/download PDF

24. Investigation of a Mobile Health Texting Tool for Embedding Patient-Reported Data Into Diabetes Management (i-Matter): Development and Usability Study (Preprint)

Author

Schoenthaler, Antoinette, primary, Cruz, Jocelyn, additional, Payano, Leydi, additional, Rosado, Marina, additional, Labbe, Kristen, additional, Johnson, Chrystal, additional, Gonzalez, Javier, additional, Patxot, Melissa, additional, Patel, Smit, additional, Leven, Eric, additional, and Mann, Devin, additional

Published
2020
Full Text
View/download PDF

25. In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Author

Li, Fei, primary, Huang, Qingyuan, additional, Luster, Troy A., additional, Hu, Hai, additional, Zhang, Hua, additional, Ng, Wai-Lung, additional, Khodadadi-Jamayran, Alireza, additional, Wang, Wei, additional, Chen, Ting, additional, Deng, Jiehui, additional, Ranieri, Michela, additional, Fang, Zhaoyuan, additional, Pyon, Val, additional, Dowling, Catríona M., additional, Bagdatlioglu, Ece, additional, Almonte, Christina, additional, Labbe, Kristen, additional, Silver, Heather, additional, Rabin, Alexandra R., additional, Jani, Kandarp, additional, Tsirigos, Aristotelis, additional, Papagiannakopoulos, Thales, additional, Hammerman, Peter S., additional, Velcheti, Vamsidhar, additional, Freeman, Gordon J., additional, Qi, Jun, additional, Miller, George, additional, and Wong, Kwok-Kin, additional

Published
2020
Full Text
View/download PDF

26. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

Author

Zhang, Hua, primary, Christensen, Camilla L., additional, Dries, Ruben, additional, Oser, Matthew G., additional, Deng, Jiehui, additional, Diskin, Brian, additional, Li, Fei, additional, Pan, Yuanwang, additional, Zhang, Xuzhu, additional, Yin, Yandong, additional, Papadopoulos, Eleni, additional, Pyon, Val, additional, Thakurdin, Cassandra, additional, Kwiatkowski, Nicholas, additional, Jani, Kandarp, additional, Rabin, Alexandra R., additional, Castro, Dayanne M., additional, Chen, Ting, additional, Silver, Heather, additional, Huang, Qingyuan, additional, Bulatovic, Mirna, additional, Dowling, Catríona M., additional, Sundberg, Belen, additional, Leggett, Alan, additional, Ranieri, Michela, additional, Han, Han, additional, Li, Shuai, additional, Yang, Annan, additional, Labbe, Kristen E., additional, Almonte, Christina, additional, Sviderskiy, Vladislav O., additional, Quinn, Max, additional, Donaghue, Jack, additional, Wang, Eric S., additional, Zhang, Tinghu, additional, He, Zhixiang, additional, Velcheti, Vamsidhar, additional, Hammerman, Peter S., additional, Freeman, Gordon J., additional, Bonneau, Richard, additional, Kaelin, William G., additional, Sutherland, Kate D., additional, Kersbergen, Ariena, additional, Aguirre, Andrew J., additional, Yuan, Guo-Cheng, additional, Rothenberg, Eli, additional, Miller, George, additional, Gray, Nathanael S., additional, and Wong, Kwok-Kin, additional

Published
2020
Full Text
View/download PDF

27. Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis.

Author

Zhang, Hua, Han, Han, He, Tianhui, Labbe, Kristen E, Hernandez, Adrian V, Chen, Haiquan, Velcheti, Vamsidhar, Stebbing, Justin, and Wong, Kwok-Kin

Subjects
COVID-19, TREATMENT effectiveness, CANCER patients, LOGISTIC regression analysis, DEATH rate, INVASIVE candidiasis
Abstract

Background: Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate.Methods: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariable logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes.Results: We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the United Kingdom and Europe, followed by the United States and Canada (35.7%), and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (OR = 3.57, 95% CI = 1.80 to 7.06), male sex (OR = 2.10, 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00, 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariable analysis, only age greater than 65 years (OR = 3.16, 95% CI = 1.45 to 6.88) and being male (OR = 2.29, 95% CI = 1.07 to 4.87) were associated with increased risk of severe events.Conclusions: Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate compared with that of COVID-19 patients without cancer. Age and sex appear to be risk factors associated with a poorer prognosis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis.

Author

Zhang H, Han H, He T, Labbe KE, Hernandez AV, Chen H, Velcheti V, Stebbing J, and Wong KK

Subjects
Asia epidemiology, COVID-19 mortality, COVID-19 virology, Canada epidemiology, Comorbidity, Europe epidemiology, Female, Humans, Male, Neoplasms mortality, Risk Factors, SARS-CoV-2 physiology, Survival Rate, United Kingdom epidemiology, United States epidemiology, COVID-19 epidemiology, Neoplasms epidemiology
Abstract

Background: Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate., Methods: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariable logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes., Results: We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the United Kingdom and Europe, followed by the United States and Canada (35.7%), and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (OR = 3.57, 95% CI = 1.80 to 7.06), male sex (OR = 2.10, 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00, 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariable analysis, only age greater than 65 years (OR = 3.16, 95% CI = 1.45 to 6.88) and being male (OR = 2.29, 95% CI = 1.07 to 4.87) were associated with increased risk of severe events., Conclusions: Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate compared with that of COVID-19 patients without cancer. Age and sex appear to be risk factors associated with a poorer prognosis., (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results